Deals
AstraZeneca’s Soriot Pumped Up the Noise on Drug Pipeline
This article is for subscribers only.
When Pascal Soriot took the helm at AstraZeneca Plc in 2012, he inherited a company with a looming patent cliff and an ailing pipeline after a string of drug development setbacks.
Now, 18 months later, Pfizer Inc. is seeking to shell out almost $100 billion, in part for that pipeline.